WO2006013016A3 - Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21) - Google Patents

Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21) Download PDF

Info

Publication number
WO2006013016A3
WO2006013016A3 PCT/EP2005/007955 EP2005007955W WO2006013016A3 WO 2006013016 A3 WO2006013016 A3 WO 2006013016A3 EP 2005007955 W EP2005007955 W EP 2005007955W WO 2006013016 A3 WO2006013016 A3 WO 2006013016A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
prss21
therapeutics
diagnostics
serine protease
Prior art date
Application number
PCT/EP2005/007955
Other languages
French (fr)
Other versions
WO2006013016A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006013016A2 publication Critical patent/WO2006013016A2/en
Publication of WO2006013016A3 publication Critical patent/WO2006013016A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The invention provides a human PRSS21 which is associated with the infections, cardiovascular diseases, respiratory diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, muscle skeleton diseases, reproduction diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of infections, cardiovascular diseases, respiratory diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, muscle skeleton diseases, reproduction diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS21 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007955 2004-08-04 2005-07-21 Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21) WO2006013016A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04018439.2 2004-08-04
EP04018439 2004-08-04

Publications (2)

Publication Number Publication Date
WO2006013016A2 WO2006013016A2 (en) 2006-02-09
WO2006013016A3 true WO2006013016A3 (en) 2006-03-30

Family

ID=35311413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007955 WO2006013016A2 (en) 2004-08-04 2005-07-21 Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)

Country Status (1)

Country Link
WO (1) WO2006013016A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444975B2 (en) 2004-12-13 2013-05-21 Alethia Biotherapeutics Inc. Method for inhibiting bone resorption

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1132768A (en) * 1997-07-16 1999-02-09 Ono Pharmaceut Co Ltd New acidocyte serine protease
WO1999029859A1 (en) * 1997-12-12 1999-06-17 Cedars-Sinai Medical Center Gene associated with neoplastic disease or malignancy associated gene
US6203979B1 (en) * 1998-01-16 2001-03-20 Incyte Pharmaceuticals, Inc. Human protease molecules
WO2001027257A1 (en) * 1999-10-14 2001-04-19 The Board Of Trustees Of The University Of Arkansas Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
US6479274B1 (en) * 1997-02-13 2002-11-12 Amrad Operations Pty., Ltd. DNA molecules encoding human HELA2 or testisin serine proteinases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479274B1 (en) * 1997-02-13 2002-11-12 Amrad Operations Pty., Ltd. DNA molecules encoding human HELA2 or testisin serine proteinases
JPH1132768A (en) * 1997-07-16 1999-02-09 Ono Pharmaceut Co Ltd New acidocyte serine protease
WO1999029859A1 (en) * 1997-12-12 1999-06-17 Cedars-Sinai Medical Center Gene associated with neoplastic disease or malignancy associated gene
US6203979B1 (en) * 1998-01-16 2001-03-20 Incyte Pharmaceuticals, Inc. Human protease molecules
WO2001027257A1 (en) * 1999-10-14 2001-04-19 The Board Of Trustees Of The University Of Arkansas Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIMES R T ET AL: "ENDOTHELIAL CELL SERINE PROTEASES EXPRESSED DURING VASCULAR MORPHOGENESIS AND ANGIOGENESIS", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 89, no. 3, March 2003 (2003-03-01), pages 561 - 572, XP009038637, ISSN: 0340-6245 *
INOUE MASAHIRO ET AL: "Structural analysis of esp-1 gene (PRSS 21)", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 266, no. 2, 20 December 1999 (1999-12-20), pages 564 - 568, XP002208048, ISSN: 0006-291X *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 05 31 May 1999 (1999-05-31) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444975B2 (en) 2004-12-13 2013-05-21 Alethia Biotherapeutics Inc. Method for inhibiting bone resorption

Also Published As

Publication number Publication date
WO2006013016A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2006010498A3 (en) Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2006013016A3 (en) Diagnostics and therapeutics for diseases associated with eosinophil serine protease 1 (prss21)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2006013012A3 (en) Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)
WO2005040401A3 (en) Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase